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We compared the Gen-Probe transcription-mediated amplification assay (AMP CT), the Abbott LCx assay,
and the Roche COBAS AMPLICOR assay for the detection of Chlamydia trachomatis in a mixed population in
urine samples. First-void urine, urethral specimens, and cervical specimens in females were obtained from
1,000 patients (544 males and 456 females) visiting the outpatient sexually transmitted disease clinic of our
hospital. The prevalence of C. trachomatis infection was 7.7% as determined by tissue culture of urethral and
cervical specimens. The sensitivities of LCx, COBAS AMPLICOR, and AMP CT compared to cell culture were
79, 86, and 78%, respectively. Sensitivity and specificity were recalculated by using a new “gold standard”, i.e.,
a sample was considered to be true positive if two or more techniques yielded positive results. Specimens
positive only by cell culture or positive in only one commercial amplification technique were retested by a
previously described in-house PCR. After discordance analysis the sensitivities of LCx, COBAS AMPLICOR,
and AMP CT were 84, 93, and 85%, respectively. Specificity exceeded 99% for all three assays. With each
method the sensitivity was lower for urine samples from females compared to urine samples from males. By
application of this new gold standard, existing differences between methods are highlighted; future evaluations
of new techniques should be validated against two or more amplification assays.
Chlamydia trachomatis is now the most common cause of
sexually transmitted diseases (4). Among other serious com-
plications, it frequently leads to infertility in women (8). Ef-
fective control of chlamydial urogenital infections has been
hampered by the lack of rapid, effective, and easy methods of
diagnosis. Isolation of C. trachomatis in cell culture has been
considered the reference method for diagnosing chlamydia for
many years (1, 29). The introduction of assays based on am-
plification of genetic material has subsequently increased the
sensitivity of detecting chlamydial infections. These amplifica-
tion techniques have first been compared to cell culture of
urethral and cervical patient specimens (19, 27).
Because of the increased sensitivity of these nucleic acid
amplification techniques, they recently have made possible the
use of urine specimens for the detection of C. trachomatis in
both men and women, thereby eliminating cumbersome sam-
pling (3, 5, 9, 14, 25). In addition, amplification assays are now
available in automated formats, standardizing performance in
clinical microbiology laboratories. These automated tech-
niques, i.e., COBAS AMPLICOR and AMP CT, are not avail-
able yet in the United States since they are still waiting for
Food and Drug Administration approval. These techniques,
however, have already been introduced on the European mar-
ket and, therefore, we were able to study the COBAS AMPLI-
COR PCR (12, 15) from Roche Diagnostic Systems (Basel,
Switzerland), the transcription-mediated amplification assay
AMP CT from Gen-Probe Inc. (San Diego, Calif.), and LCx of
Abbott Laboratories (Chicago, Ill.) for the detection of C.
trachomatis in first-void urine and compare the results with
those of tissue culture of cervical and/or urethral specimens.
MATERIALS AND METHODS
Patient population and specimen handling. Specimens were collected from
544 men and 456 women visiting the outpatient department of sexually trans-
mitted diseases (STD) at the University Hospital of Rotterdam, The Nether-
lands, from February 1996 to July 1996. To determine sample-to-sample varia-
tion due to order of collection, the samples were collected in a block design of
250 samples each in the following order for females: block 1, cervical swab (CS),
urethral swab (US), first-void urine (FVU); block 2, FVU, CS, US; block 3, CS,
US, FVU; block 4, FVU, CS, US for females. For males the order of collection
was US, FVU over all blocks. The chlamydial culture samples were collected with
ENT Dacron swabs (Medical Wire, Corsham, United Kingdom), placed in 0.2 M
sucrose phosphate buffer, and stored at 4°C or, when not tested within 24 h after
collection, at 270°C. The volume of urine collected was 40 to 50 ml. Urine
specimens were stored and processed according to the instructions of the man-
ufacturer.
Cell culture. Chlamydial culture was performed on cycloheximide-treated Mc-
Coy cells in microtiter plates and has been described extensively (16, 17, 30).
Briefly, two wells per plate were each inoculated with 0.2 ml of a patient sample.
After centrifugation for 60 min at 1,400 3 g, the supernatant was replaced with
0.1 ml of complete growth medium (Eagle minimal essential medium with Glu-
tamax; Flow Laboratories Inc., Paisley, Scotland) containing 10% fetal calf se-
rum (Flow), 1% vitamins (Flow), and 20 mg of gentamicin, 5 mg of amphotericin
B, 25 mg of vancomycin, 4.5 g of glucose, and 1 mg of cycloheximide (Sigma
Chemical Co., St. Louis, Mo.) (pH 7.5) per liter. The plates were incubated at
37°C at 5% CO2 for 48 h. Thereafter, the monolayers were fixed with ethanol
(96%) for 10 min and stained with a fluorescent monoclonal antibody (Micro-
trak; Syva Co., Palo Alto, Calif.) specific for C. trachomatis and examined for
inclusions. Culture results (two wells) were scored as follows: negative, no in-
clusions; 11, 1 to 5 inclusions; 21, 6 to 20 inclusions; 31, .20 inclusions.
AMP CT. The AMP CT procedure was carried out according to the instruc-
tions of the manufacturer. Briefly, the urine samples were incubated for 10 min
at 37°C followed by centrifugation of 1.5 ml of the specimen at 8,000 3 g for 5
min. The supernatant was decanted, and the pellet was resuspended in 200 ml of
specimen diluent buffer. Twenty-five microliters of amplification reagent was
added to the propylene reaction tubes. After 200 ml of oil reagent was added to
the reaction tube, 50 ml of processed specimen was pipetted under the oil
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reagent. The tubes were incubated for 10 min at 95°C in a heating block (Diag-
nostic Grifols S.A., Barcelona, Spain). After cooling down in a heating block at
42°C for 5 min, 25 ml of enzyme reagent was added. After incubation for 1 h at
42°C, 20 ml of termination reagent was added, and the mixture was incubated
again for 10 min at 42°C. After addition of 100 ml of probe reagent, the tubes
were briefly vortexed and incubated for 15 min at 60°C in a water bath. After 300
ml of selection reagent was added, the tubes were incubated for 10 min at 60°C
in the water bath and cooled down for 10 min at room temperature. The
hybridization protection assay with acridinium-ester-labeled DNA probes spe-
cific for the target organism was used for detection. Positive and negative con-
trols were included in every run. All pipetting was done by using aerosol-resistant
tips.
LCx. For LCx, 1 ml of FVU was pipetted in a 1.7-ml microcentrifuge tube, and
the tube was centrifuged at 15,000 3 g for 15 min (Eppendorf centrifuge 5415C;
Netheler Hinz, GmbH, Hamburg, Germany). The supernatant was replaced with
1 ml of urine resuspension buffer (provided with the LCx kit), and the tubes were
placed in a heating block (95 to 100°C) for 15 min. After cooling to room
temperature, the samples were tested immediately by LCx or were stored at
220°C for future testing.
The LCx assay was performed and evaluated according to manufacturer’s
instructions. Briefly, 100 ml of the processed urine was transferred to individual
LCx unit-dose tubes containing 100 ml of the LCx mixture (four oligonucleotides
specific for the C. trachomatis plasmid, DNA ligase, polymerase, NAD1, Mg21,
dCTP, and dTTP in a pH 7.8 buffer). Two positive and negative controls as well
as two calibrators were assayed with each batch of samples. The samples were
processed in a thermocycler (model 480; Perkin-Elmer Cetus, Norwalk, Conn.)
for 40 cycles of 1 s at 97°C, 1 s at 55°C, and 50 s at 62°C. The controls, calibrators,
and samples were then centrifuged at 8,000 3 g for 1 s and were transferred to
the LCx reaction cells. Amplification products were qualitatively detected in an
LCx analyzer.
COBAS AMPLICOR PCR. The COBAS AMPLICOR test was performed
according to the manufacturer’s instructions. In brief, 0.5 ml of wash buffer was
added to a 1.5-ml reaction tube. Subsequently, 0.5 ml of well-mixed urine was
added to the tube containing the wash buffer. This mix was incubated for 15 min
at 37°C, followed by centrifugation at 14,000 3 g for 5 min at room temperature.
The supernatant was discarded, and the pellet was resuspended with 0.25 ml of
lysis buffer, vortexed, and incubated for 15 min at room temperature. An equal
volume (0.25 ml) of specimen diluent buffer (Roche Diagnostic Systems) was
added immediately after incubation. The tubes were vortexed thoroughly and
centrifuged at 14,000 3 g for 10 min. Fifty microliters of the supernatant was
transferred to amplification tubes.
COBAS AMPLICOR C. trachomatis is performed in a multiplex format in-
cluding C. trachomatis, Neisseria gonorrhoeae, and an internal control. The in-
ternal control of amplification in the COBAS AMPLICOR assay is a sequence
of plasmid DNA with primer-binding regions identical to those of the C. tracho-
matis target sequence and a randomized internal sequence with a length and base
composition similar to those of the C. trachomatis target sequence. A unique
probe-binding region differentiates the internal control from the target amplicon.
The internal control is introduced into each amplification reaction and is coam-
plified with the possible target DNA from the clinical specimen.
The amplified nucleotide sequences for the internal control and C. trachomatis
were automatically detected by using target-specific DNA probes coated on
magnetic particles. The A660s were measured by the built-in spectrophotometer.
All pipetting was performed with micropipettes with aerosol barrier tips.
In-house PCR. (i) Urine. The urine samples were thawed at room temperature
and vortexed, and 1.5 ml was transferred to a clean tube and incubated for 15 min
at 37°C. The specimens were then centrifuged for 30 min at 14,000 3 g at 37°C.
The supernatant was removed, and the pellet was treated with 80 ml of lysis buffer
(50 mM Tris-HCl [pH 7.5], 1% Triton X-100, 1 mM EDTA, and 250 mg of
proteinase K per ml). After incubation at 37°C for 1 h the DNA in the lysates was
extracted and purified with 4 M guanidine-isothiocyanate and Celite according to
the method of Boom et al. (6). At the final step the DNA was eluted in 100 ml
of 10 mM Tris-HCl (pH 8.0).
(ii) Cervical and urethral swabs. Specimens for PCR analysis were treated as
described before (13). Briefly, a 400-ml sample was centrifuged for 30 min at
14,000 3 g, and the pellet was treated with 40 ml of lysis buffer. After incubation
at 37°C for 1 h, the lysates were boiled for 10 min and centrifuged briefly. From
each lysate, 8 ml was added to 92 ml of the PCR mixture.
(iii) Primers and PCR protocol. PCR was performed in a 100-ml volume under
standard conditions with 8 ml of the DNA sample. Primers recognizing sequences
of the endogenous plasmid of C. trachomatis were used: T1, GGACAAATCGT
ATCTCGG; T2, GAAACCAACTCTACGCTG. PCR was performed in 100 ml
of the PCR solution, containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2.5 mM
MgCl2, 200 mM each deoxynucleoside triphosphate, 50 pmol of each primer, 0.1
mg of gelatin per ml, 0.2 U of Taq DNA polymerase (Sphaero-Q, Leiden, The
Netherlands), and 8 ml of the sample. The reaction mixture was overlaid with 100
ml of mineral oil (Sigma) to prevent evaporation and was preincubated for 5 min
at 94°C for DNA denaturation. Forty cycles of amplification were performed
with a PCR processor (Biomed GmbH, Theres, Germany). Each cycle consisted
of a denaturation step at 94°C for 1 min, a primer-annealing step at 55°C for 1
min, and a chain elongation step at 74°C for 2 min. After 40 cycles, a temperature
delay step of 5 min at 74°C completed elongation. A 40-ml volume of the
amplified PCR product was analyzed by agarose (1.5%, wt/vol) gel electrophore-
sis.
(iv) Southern blot analysis of PCR products. DNA was transferred from
agarose to Hybond-plus nylon filters (Amersham International, Amersham,
United Kingdom) by electrophoretic transfer. The PCR products were analyzed
with a C. trachomatis-specific probe (CGCAGCGCTAGAGGCCGGTCTATT
TATGAT).
Analysis of results. Discordant analysis was based on a classical comparison of
cell culture and, for example, LCx. The in-house PCR was performed first on
FVU; if this result was negative, the in-house PCR was performed on the US
and/or CS samples. A cell culture-negative and LCx-positive result was consid-
ered to be confirmed positive if the in-house PCR on FVU was positive. If the
in-house PCR was negative, the LCx result was considered to be false positive. A
culture-positive positive and LCx-negative result was considered to be false
negative if the FVU was positive by the in-house PCR. If the FVU by the
in-house PCR was negative and the US and/or CS specimen was positive by the
in-house PCR, the LCx was considered false negative due to sample-to-sample
variation. If the FVU, US, and CS (if applicable) remained negative by the
in-house PCR, DNA was isolated from the inoculated cell culture monolayers
and subjected to PCR. The cell culture result was considered true positive if the
inoculated monolayer was confirmed by the in-house PCR of the scraped mono-
layer. Similar discordant analyses were performed for cell culture versus AMP
CT and cell culture versus COBAS AMPLICOR. In an alternative discrepancy
analysis, true-positive patients were identified. A result was considered true
positive if two or more diagnostic assays were positive. All discrepant results
were confirmed by using the in-house PCR, which was performed on the FVU,
US, and CS samples, if applicable. If the in-house PCR did not confirm the
positive result, the result was considered false positive. If a cell culture-positive
result could not be confirmed by any of the three commercial amplification
techniques or by the in-house PCR of the FVU, CS, and US samples, DNA was
isolated from the inoculated cell culture monolayers and subjected to the in-
house PCR. The cell culture result of the discrepant specimen was considered
true positive if the in-house PCR of the scraped monolayer was positive.
Statistics. All demographic data and laboratory results were coded, entered
into a database, and subjected to standard verification procedures. The data were
analyzed by using SPSS for Windows 95, version 7.0. Statistical evaluation of the
collected data was performed by using Fisher’s exact test. Probability values were
two-tailed.
RESULTS
FVU, US, and, for females, CS specimens from 1,000 pa-
tients visiting the outpatient STD clinic were obtained. Cell
cultures of US and CS specimens were positive for 37 male and
40 female patients, resulting in a prevalence of 6.8 and 8.8%,
respectively. Of these 77 culture-positive patients 61, 60, and
66 were detected by LCx, AMP CT, and COBAS AMPLICOR,
respectively. Seventy-one of 77 cell-culture-positive samples
were also positive in at least one of the three amplification
techniques and were thus considered true positives. All three
commercial techniques detected many additional positives. For
the additional positives a discordant analysis was performed to
rule out false positivity. Discordant analysis was performed by
using the in-house PCR on FVU specimens. This resulted in 97
LCx-, 98 AMP CT-, and 106 COBAS AMPLICOR-positive
samples.
The six urine specimens obtained from patients who were
culture positive but negative in all three amplification assays
were analyzed separately by performing a DNA extraction
procedure on the monolayers of these samples followed by
PCR. None of the six yielded a positive PCR signal, and the
cell culture results were, therefore, considered false positive.
Thus, 71 true cell culture-positive specimens remained.
Specimens negative by cell culture but positive by an ampli-
fication assay and confirmed by the in-house PCR on FVU
were regarded as confirmed positives, resulting in 36 LCx, 38
AMP CT, and 40 COBAS AMPLICOR confirmed positives.
For calculating the sensitivities and specificities of the three
assays after this discrepancy analysis, a new “gold standard”
was defined as confirmed cell culture positives also confirmed
by each of the amplification techniques. This resulted in sen-
sitivities for the LCx, AMP CT, and COBAS AMPLICOR of
90.7, 89.9, and 95.5%, respectively (Fig. 1).
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The remaining 7 LCx-, 15 AMP CT-, and 13 COBAS AM-
PLICOR-positive samples that were negative by the in-house
PCR on FVU were analyzed further by performing the in-
house PCR on the CS or US samples of the same patients. For
the three assays, four, six, and six samples, respectively, could,
thus, be confirmed and were regarded as true-positive samples.
This finally resulted in 40 LCx, 44 AMP CT, and 46 COBAS
AMPLICOR additional positives, respectively, for 101 LCx-,
104 AMP CT-, and 112 COBAS AMPLICOR-positive sam-
ples. The total numbers of positives increased to 111, 115, and
117 for LCx, AMP CT, and COBAS AMPLICOR, respec-
tively. These additional positives resulted in small increases of
the earlier-calculated sensitivities of the three commercial as-
says to 91, 90.4, and 95.7%, respectively, and small increases in
specificity.
Alternative discrepant analysis. The aforementioned dis-
crepant analysis was performed to define a specimen as con-
firmed positive, for each technique separately. Another line of
reasoning which we followed was to identify truly C. tracho-
matis-infected patients.
Since in this prospectively controlled study the three tech-
niques were evaluated by using one and the same urine spec-
imen, we do not have to take into account sample-to-sample
variation due to the order of specimen collection. Therefore,
we introduced a new gold standard, i.e., truly C. trachomatis-
infected patients. Specimens not confirmed by one of the com-
mercial assays were analyzed by using the in-house PCR on
FVU, CS, or US specimens. By the LCx technique, initially 43
patients were determined to be positive. Of these 43, 41 were
confirmed by another commercial technique and one was con-
firmed by the in-house PCR. One specimen could not be con-
firmed and was considered false positive. Results for the other
two techniques are given in Table 1.
By using this new gold standard, a total of 123 patients (71
culture-positive plus 52 confirmed) were considered truly in-
FIG. 1. Cell culture results versus the results of the amplification assays and results of discordant analysis of additional positives by in-house PCR on FVU.
TABLE 1. Number of positives detected by each technique
exclusively and confirmed by a commercial assay or by in-house PCR
Assay
(no. of positives)
No. of patients confirmed
AMP CT
or COBAS
AMPLICOR
LCx or
COBAS
AMPLICOR
LCx
or
AMP
CT
In-
house
PCRa
Total
LCx (43) 41 1 42
AMP CT (53) 42 3 45
COBAS AMPLICOR (53) 47 1 48
a FVU, CS, or US.
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fected by C. trachomatis (prevalence of 12.3%). With these
new findings, sensitivity and specificity were recalculated by
using the above-mentioned definition (Table 2). The revised
sensitivities of LCx, AMP CT, and COBAS AMPLICOR were
84, 85, and 93%, respectively. Specificity exceeded 99% for all
amplification techniques.
With this new gold standard the sensitivity of tissue culture
was only 58%, significantly lower than the sensitivities of the
amplification methods. Furthermore, it can be seen that with
all three amplification techniques the sensitivity for detecting a
C. trachomatis infection in urine specimens is lower for females
than for males.
DISCUSSION
Most papers describing an evaluation of a commercial am-
plification technique, i.e., PCR, LCx, or AMP CT, with urine
specimens report sensitivities of 92 to 99% and excellent spec-
ificities (3, 5, 9, 14, 24). So far, no direct comparison of the
three automated amplification methods has been published. In
the present study we were able to evaluate COBAS AMPLI-
COR versus LCx and AMP CT on one and the same specimen.
The results of LCx, AMP CT, and COBAS AMPLICOR were
analyzed separately versus cell culture, in order to calculate the
sensitivity and specificity as if they were evaluated in a separate
study. With this method, no statistically significant differences
were demonstrated between the three commercially available
amplification techniques (sensitivities of 91.0, 90.4, and 95.7%,
respectively).
In addition, we introduced a new gold standard, i.e., the
ability of a test to identify truly infected patients. With this new
gold standard sensitivity was 83.7% for LCx, 85.4% for AMP
CT, and 92.7% for COBAS AMPLICOR; the difference in
sensitivity between the COBAS AMPLICOR and LCx reached
statistical significance (P 5 0.047). No statistically significant
difference (P 5 0.101) between COBAS AMPLICOR and the
AMP CT was found, although a similar trend was observed.
These results are not in complete accordance with those re-
ported by other authors regarding the sensitivities of the indi-
vidual assays (3, 5, 9, 14, 24). One should realize that the
previously published data were obtained mainly in a male pop-
ulation, a fact that could be used as an argument to explain the
differences demonstrated (3, 14). However, recently LCx and
COBAS AMPLICOR have also been evaluated with samples
from females with excellent sensitivity scores (2, 18, 23). Even
if the sensitivities of the assays are calculated solely for the
male population, there is still a significant difference between
the LCx (87.9%), AMP CT (92.4%), and COBAS AMPLI-
COR (97%). The explanation for the differences between the
present data and the previously reported data must be related
to the reference method applied. This is best demonstrated by
evaluating our own data. In a previous study (13) at our insti-
tute, a prevalence of 7.8% by tissue culture for C. trachomatis
infection was reported. In that study an in-house PCR on US
and CS specimens was evaluated. After discordant analysis a
total of 110 true-positive patients were identified, giving rise to
an actual prevalence of 9.9%. With PCR, 102 of 110 were
detected, giving a sensitivity of 92.7%, whereas tissue culture
had a sensitivity of 79.1% only.
In the present study prevalence by tissue culture was 7.1%,
indicating that no great shift has occurred in prevalence in this
particular patient cohort. If COBAS AMPLICOR is regarded
as the reference method, the sensitivity of tissue culture is
63.9% (71 of 111). Another example demonstrating the role of
the reference method used was reported previously by our
group. We analyzed AMP CT versus cell culture (21) by mak-
ing use of the same specimens. The overall sensitivity for AMP
CT was 92.4%. In the present study the initial sensitivity for
AMP CT was 89.9%. The role of the reference method in the
evaluation of the three assays is even more evident with the
introduction of the new gold standard, i.e., truly infected pa-
tients. Truly infected patients are defined as those who are
positive by two of the four assays used, i.e., three amplification
assays and cell culture. By this measure the initially reported
sensitivity of tissue culture further decreases to 57.7%.
The differences between the sensitivities of the three ampli-
fication assays are not due to a difference in initial accuracy
between the assays, since we diluted several C. trachomatis-
positive patient samples with a 10-fold limiting dilution series
and assayed these samples separately in the three amplification
assays. No significant differences were observed between the
three amplification assays (data not shown). Therefore, the
differences have to be due to other factors. One of these
factors could be overdilution of C. trachomatis by the urine
volume collected. Abbott advises a maximum volume of 20 ml,
and Roche advises a maximum volume of 50 ml. In this study
we collected volumes of 40 to 50 ml. On the other hand, an
excess in volume collected could also be beneficial in the sense
that inhibitors are also diluted, influencing the sensitivity in a
positive way. Another, more technical complication could be
related to the volume added into the amplification assay. The
initial volumes of the urine specimens used for amplification in
AMP CT, LCx, and COBAS AMPLICOR are 1.5, 1, and 0.5
ml, respectively. Of these specimen volumes, 375, 100, and 50
ml, respectively, are included in the amplification reaction. On
the basis of this calculation, one would conclude that the LCx
technique, despite using twice the amount of the volume used
in COBAS AMPLICOR, produces fewer positives, possibly
due to a less accurate amplification/detection procedure. An-
other explanation would be that the pretreatment procedure of
TABLE 2. Detection of true C. trachomatis infectionsa by cell culture and amplification assays
Method
No. of patients positive (%)b
% Sensitivity
(CI95)c
%
SpecificityFemales
(n 5 57)
Males
(n 5 66)
Cell culture 37 (64.9) 34 (51.5) 57.7 (48.4–66.6) 99.3
LCx 45 (78.9) 58 (87.9) 83.7 (75.9–89.9) 99.9
AMP CT 44 (77.2) 61 (92.4) 85.4 (77.8–91.1) 99.1
COBAS AMPLICOR 50 (87.7) 64 (97) 92.7 (86.6–96.6) 99.4
a Truly infected patients (n 5 123) are defined as patients whose urine specimens tested positive by two or more techniques or whose CS or US specimens were
confirmed by the in-house PCR.
b No statistical significance was obtained for COBAS AMPLICOR versus LCx or AMP CT after analysis of the female or male results separately.
c Statistical significance was obtained for COBAS AMPLICOR versus LCx (P 5 0.047). No statistical significance was obtained for COBAS AMPLICOR versus AMP
CT (P 5 0.101). CI95, 95% confidence interval.
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LCx is insufficient for neutralizing inhibitory substances. Other
studies in which LCx was evaluated also reported a strikingly
high number of false-negative results, most likely due to the
presence of LCx inhibitors in urine specimens (26, 31).
AMP CT, on the other hand, used 375 ml of the initial urine
specimen in the amplification procedure. However, even with
an initial specimen 3.75 and 7.5 times larger than those used
for LCx and COBAS AMPLICOR, this technique was not able
to detect all positive specimens. The enzymes used in this
amplification assay, however, are obviously not that vulnerable
to inhibitory substances. The problem with these amplification
techniques is that they seem to suffer from unfavorable ratios
of target DNA or RNA to aspecific DNA or RNA and to
inhibitory substances present in the processed sample. Proba-
bly all three techniques have some of these shortcomings. It
seems, however, that at the moment COBAS AMPLICOR
suffers less from these shortcomings since Roche Diagnostic
Systems has reduced the initial volume size of the urine spec-
imen from 8 to 0.5 ml, thereby reducing the volume used in the
PCR twofold. In earlier papers sensitivities of 62 and 82% were
reported (11, 28); it was recommended that 8 ml of urine be
processed. The present results show that this reduction in
volume has actually led to an increased sensitivity, which points
to the presence of inhibitory substances in urine. In addition,
Roche Diagnostics has also introduced an internal control in
their diagnostic assay, thereby optimizing the detection rate of
the assay. In the present study 26 patients (2.6%) had results
indicating inhibition of the PCR. Only one specimen remained
inhibited after being heated at 95°C for 10 min (data not
shown). Since the introduction of COBAS AMPLICOR in our
laboratory, 59 inhibited samples were detected, of which 14
became positive for C. trachomatis after heat treatment, indi-
cating the necessity of an internal standard (data not shown).
It has become evident that the sensitivity of cell culture does
not meet the demands of a reference method for nucleic acid
amplification techniques. Therefore, in the present study we
used the summary data of three independent amplification
techniques combined with cell culture as an expanded gold
standard. By applying this strict reference, the existing differ-
ences between methods are highlighted. In future evaluations
of amplification techniques it should be emphasized that new
techniques should be validated against two or more other am-
plification assays in combination with cell culture.
Our data for the three techniques show a reduced sensitivity
for detection of C. trachomatis infections in females. AMP CT
and LCx demonstrated unacceptably low sensitivities for the
female population and, therefore, cannot be recommended as
reliable methods for the detection of C. trachomatis infection
in females. The explanation for these findings probably has to
do with the fact that the pathology of chlamydia infection is
localized mainly in the cervix, with a relatively low percentage
of cases involving also infection of the urethra (7, 20, 22).
However, Pasternak et al. (23) and Chernesky et al. (10)
claimed that they detected more positives in urine specimens
than in cervical specimens, indicating that the endocervix may
actually not be infected in some of these patients. Preliminary
analysis by PCR of swab specimens obtained in this study do
confirm these findings (data not shown). Of the 42 female C.
trachomatis FVU-positive patients, only 35 and 33 tested pos-
itive by CS and US, respectively. Of the 44 male C. trachomatis
FVU-positive patients, 39 were positive by US. The previously
reported results and our preliminary results, however, may be
influenced by the presence of PCR and cell culture inhibitors
in cervical materials. Thus, we feel that for the female popu-
lation urine screening for C. trachomatis needs to be further
improved or supplemented by swab specimens from the cervix,
and there remains room for improvement of these recently
introduced test systems.
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